• Heights Capital Management cut its total stake in Faron Pharmaceuticals to 19.96% on Sept. 14, from 20.25% previously.
• Shareholding fell to 8.66%, representing 19,735,191 voting rights.
• Exposure via Convertible Bond instruments stayed at 11.3%, representing 25,760,000 voting rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609170215ACCESSWRNAPR_____1222866) on September 17, 2026, and is solely responsible for the information contained therein.